Etoposide pharmacokinetics and survival in patients with small cell lung cancer: A multicentre study

Lung Cancer

Volumn 62, Issue 2, 2008, Pages 261-272

  You, Benoit ^a,b,c   Tranchand, Brigitte ^a,b,d   Girard, Pascal ^a,b   Falandry, Claire ^a,b,c   Ribba, Benjamin ^a,b   Chabaud, Sylvie ^d   Souquet, Pierre Jean ^c   Court Fortune, Isabelle ^e   Trillet Lenoir, Véronique ^a,b,c   Fournel, Cécile ^a,b,c   Tod, Michel ^a,b,f   Freyer, Gilles ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d CENTRE LÉON BÉRARD   (France)

^e HÔPITAL NORD   (France)

^f Hôpital Nord ^*  (France)

Author keywords

Area Under Curve; Etoposide; Lung cancer; Pharmacodynamics; Pharmacokinetics; Prognosis; Survival

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CARBOPLATIN; CISPLATIN; CREATININE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; BAYES THEOREM; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BODY SURFACE; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY FAILURE; LIVER METASTASIS; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PLEURA METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; THROMBOCYTOPENIA; UNIVARIATE ANALYSIS; VOMITING;

EID: 55249103429     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.03.008     Document Type: Article

References (46)

1. Hainsworth J.D., and Greco F.A. Etoposide: twenty years later. Ann Oncol 6 4 (1995) 325-341
2. Slevin M.L. Low-dose oral etoposide: a new role for an old drug?. J Clin Oncol 8 10 (1990) 1607-1609
3. Dooley M.J., and Poole S.G. Poor correlation between body surface area and glomerular filtration rate. Cancer Chemother Pharmacol 46 6 (2000) 523-526
4. Freyer G., Tranchand B., Ligneau B., Ardiet C., Souquet P.J., Court-Fortune, et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study 3. Br J Clin Pharmacol 50 4 (2000) 315-324
5. Mascaux C., Paesmans M., Berghmans T., Branle F., Lafitte J.J., Lemaitre F., et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis 1. Lung Cancer 30 1 (2000) 23-36
6. Sundstrom S., Bremnes R.M., Kaasa S., Aasebo U., Hatlevoll R., Dahle R., et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20 24 (2002) 4665-4672
7. Pujol J.L., Daures J.P., Riviere A., Quoix E., Westeel V., Quantin X., et al. Etoposide plus cisplatin with or without the combination of 4′-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 93 4 (2001) 300-308
8. Thatcher N., Girling D.J., Hopwood P., Sambrook R.J., Qian W., and Stephens R.J. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18 2 (2000) 395-404
9. Leyvraz S., Perey L., Rosti G., Lange A., Pampallona S., Peters R., et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 17 11 (1999) 3531-3539
10. Nguyen L., Chatelut E., Chevreau C., Tranchand B., Lochon I., Bachaud J.M., et al. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 41 2 (1998) 125-132
11. Jodrell D.I., Egorin M.J., Canetta R.M., Langenberg P., Goldbloom E.P., Burroughs J.N., et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10 4 (1992) 520-528
12. Milano G., Etienne M.C., Renee N., Thyss A., Schneider M., Ramaioli A., et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12 6 (1994) 1291-1295
13. Santini J., Milano G., Thyss A., Renee N., Viens P., Ayela P., et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59 2 (1989) 287-290
14. Freyer G., Ligneau B., Tranchand B., Ardiet C., Souquet P.J., Court-Fortune, et al. The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT). Lung Cancer 31 2-3 (2001) 247-256
15. Tranchand B., Amsellem C., Chatelut E., Freyer G., Iliadis A., Ligneau B., et al. A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 43 4 (1999) 316-322
16. Beal S.L., Sheiner L.B., and Boeckmann A. NONMEM users guides (2006), Icon Development Solutions, Ellicott City, Maryland
17. Davidian M., and Giltinan D.M. Nonlinear models for repeated measurement data (1995), Chapman & Hall, London
18. Davidian M., and Giltinan D.M. Nonlinear models for repeated measurement data: an overview and update. J Agric Biol Environ Stat 8 4 (2003) 387-419
19. Dartois C., Brendel K., Comets E., Laffont C.M., Laveille C., Tranchand B., et al. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol (2007)
20. Brendel K., Dartois C., Comets E., Lemenuel-Diot A., Laveille C., Tranchand B., et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46 3 (2007) 221-234
21. Sheiner L., and Grasela T.J. An introduction to mixed effects modeling: concepts, definitions and justification. J Pharmacokinet Biopharm 19 Suppl. 3 (1991) S11-S24
22. Wahlby U., Jonsson E.N., and Karlsson M.O. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28 3 (2001) 231-252
23. Wahlby U., Bouw M.R., Jonsson E.N., and Karlsson M.O. Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn 29 3 (2002) 251-269
24. Collett D. Modelling survival data in medical research (1994), Chapman & Hall
25. Freedman L.S. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1 2 (1982) 121-129
26. Husband J.E., Schwartz L.H., Spencer J., Ollivier L., King D.M., Johnson R., et al. Evaluation of the response to treatment of solid tumours-a consensus statement of the International Cancer Imaging Society. Br J Cancer 90 12 (2004) 2256-2260
27. Schemper M., and Smith T.L. A note on quantifying follow-up in studies of failure time. Control Clin Trials 17 4 (1996) 343-346
28. Canal P., Chatelut E., and Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 56 6 (1998) 1019-1038
29. Baker S.D., Verweij J., Rowinsky E.K., Donehower R.C., Schellens J.H., Grochow L.B., et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 94 24 (2002) 1883-1888
30. Arbuck S.G., Douglass H.O., Crom W.R., Goodwin P., Silk Y., Cooper C., et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 4 11 (1986) 1690-1695
31. Ciccolini J., Monjanel-Mouterde S., Bun S.S., Blanc C., Duffaud F., Favre R., et al. Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. Ther Drug Monit 24 6 (2002) 709-714
32. D'Incalci M., Rossi C., Zucchetti M., Urso R., Cavalli F., Mangioni C., et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 46 5 (1986) 2566-2571
33. Toffoli G., Corona G., Sorio R., Robieux I., Basso B., Colussi A.M., et al. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol 52 5 (2001) 511-519
34. Kerbusch T., de K.J., Keizer H.J., van Putten J.W., Groen H.J., Jansen R.L., et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 40 1 (2001) 41-62
35. Bisogno G., Cowie F., Boddy A., Thomas H.D., Dick G., and Pinkerton C.R. High-dose cyclosporin with etoposide-toxicity and pharmacokinetic interaction in children with solid tumours. Br J Cancer 77 12 (1998) 2304-2309
36. Zucchetti M., Pagani O., Torri V., Sessa C., D'Incalci M., De F.M., et al. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer. Clin Cancer Res 1 12 (1995) 1517-1524
37. Higa G.M., Sarkar M.A., and DeVore R.F. Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma. Pharmacotherapy 19 1 (1999) 101-107
38. Clark P.I., Slevin M.L., Joel S.P., Osborne R.J., Talbot D.I., Johnson P.W., et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12 7 (1994) 1427-1435
39. Perdaems N., Bachaud J.M., Rouzaud P., Murris-Espin M., Hermant C., Mihura J., et al. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. Eur J Clin Pharmacol 54 9-10 (1998) 677-683
40. Edick M.J., Gajjar A., Mahmoud H.H., van de Poll M.E., Harrison P.L., Panetta J.C., et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 21 7 (2003) 1340-1346
41. Albain K.S., Crowley J.J., LeBlanc M., and Livingston R.B. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 8 9 (1990) 1563-1574
42. Paesmans M., Sculier J.P., Lecomte J., Thiriaux J., Libert P., Sergysels R., et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89 3 (2000) 523-533
43. Panetta J.C., Wilkinson M., Pui C.H., and Relling M.V. Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. J Pharmacokinet Pharmacodyn 29 2 (2002) 171-188
44. Ratain M.J., Mick R., Schilsky R.L., Vogelzang N.J., and Berezin F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9 8 (1991) 1480-1486
45. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 11 (1989) 1748-1756
46. Chatelut E., Canal P., Brunner V., Chevreau C., Pujol A., Boneu A., et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87 8 (1995) 573-580